Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
International Journal of Hematology
Published in: International Journal of Hematology 1/2008

01-07-2008 | Letter to the Editor

Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation

Authors: Daigo Akahane, Yoshikazu Ito, Masahiko Sumi, Tetsuzo Tauchi, Yukihiko Kimura, Kazuma Ohyashiki

Published in: International Journal of Hematology | Issue 1/2008

Login to get access

Excerpt

Allogeneic hematopoietic stem cell transplantation (HSCT) used to be a mainstay of treatment strategy for relatively young patients with chronic myeloid leukemia (CML) before the introduction of imatinib mesylate (IM). Relapse after more than 5 years is rare in HSCT-treated CML patients, and only a limited number of CML patients who relapsed after 10 years of HCST have been reported. We report on a CML patient who relapsed with chronic phase disease 14 years after HSCT. The presence of this case suggests the possibility that CML stem cells may remain quiescent for more than 10 years and have the capability of re-growth in post-transplant patients. …
Literature
1.
Horowitz MM, Gale RP, Sondel PM, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555–62.PubMed
2.
Socie G, Clift RA, Blaise D, et al. Busulphan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98:3569–74.CrossRefPubMed
3.
Goldman JM, Rizzo JD, Jabocinski KA, et al. Long term outcome after allogeneic stem cell transplantation for CML [abstract]. Hematol J. 2004;5:98. Abstract no. 266.
4.
Yong ASM, Goldman JM. Case report relapse of chronic myeloid leukaemia 14 years after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1999;23:827–8.CrossRefPubMed
5.
Kearney P, Suter M, Biggs JC. Rapid clonal development in a relapsed CML 11 years post replete allogeneic bone marrow transplantation. Leukemia Res. 2002;26:111–5.CrossRef
6.
Robin M, Guardiola P, Devergie A. A 10-year median follow up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia. 2005;19:1613–20.CrossRefPubMed
7.
Radich JP, Gooley T, Bryant E, et al. The significance of bcr-abl molecular detection in chronic myeloid leukemia patients “late,” 18 months or more after transplantation. Blood. 2001;98:1701–7.CrossRefPubMed
8.
van Rhee F, Lin F, Cross NCP. Detection of residual leukaemia more than 10 years after allogeneic bone marrow transplantation for chronic myelogenous leukaemia. Bone Marrow Transplant. 1994;14:609–12.PubMed
9.
Goldman JM, Gordon M. Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma. 2006;47:1–7.CrossRefPubMed
10.
Jamieson CHM, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl J Med. 2004;351:657–67.CrossRefPubMed
Metadata
Title
Relapse of chronic myeloid leukemia-chronic phase 14 years after allogeneic hematopoietic stem cell transplantation
Authors
Daigo Akahane
Yoshikazu Ito
Masahiko Sumi
Tetsuzo Tauchi
Yukihiko Kimura
Kazuma Ohyashiki
Publication date
01-07-2008
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 1/2008
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-008-0092-5

Other articles of this Issue 1/2008

International Journal of Hematology 1/2008 Go to the issue

Rapid Communication

Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population

Case Report

Nocardia exalbida brain abscess in a patient with follicular lymphoma

Original Article

Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation

Original Article

Periostin and bone marrow fibrosis

Progress in Hematology

Body iron metabolism and pathophysiology of iron overload

Letter to the Editor

All-trans-retinoic acid as a possible cause of acute pancreatitis even in the absence of hypertriglyceridemia
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits